281 research outputs found
Phosphorylation-mediated regulation of alternative splicing in cancer
Alternative splicing (AS) is one of the key processes involved in the regulation of gene expression in eukaryotic cells. AS catalyzes the removal of intronic sequences and the joining of selected exons, thus ensuring the correct processing of the primary transcript into the mature mRNA. The combinatorial nature of AS allows a great expansion of the genome coding potential, as multiple splice-variants encoding for different proteins may arise from a single gene. Splicing is mediated by a large macromolecular complex, the spliceosome, whose activity needs a fine regulation exerted by cis-acting RNA sequence elements and trans-acting RNA binding proteins (RBP). The activity of both core spliceosomal components and accessory splicing factors is modulated by their reversible phosphorylation. The kinases and phosphatases involved in these posttranslational modifications significantly contribute to AS regulation and to its integration in the complex regulative network that controls gene expression in eukaryotic cells. Herein, we will review the major canonical and noncanonical splicing factor kinases and phosphatases, focusing on those whose activity has been implicated in the aberrant splicing events that characterize neoplastic transformation
The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival
NEK2 is a serine/threonine kinase that promotes centrosome splitting and ensures correct chromosome segregation during the G2/M phase of the cell cycle, through phosphorylation of specific substrates. Aberrant expression and activity of NEK2 in cancer cells lead to dysregulation of the centrosome cycle and aneuploidy. Thus, a tight regulation of NEK2 function is needed during cell cycle progression. In this study, we found that NEK2 localizes in the nucleus of cancer cells derived from several tissues. In particular, NEK2 co-localizes in splicing speckles with SRSF1 and SRSF2. Moreover, NEK2 interacts with several splicing factors and phosphorylates some of them, including the oncogenic SRSF1 protein. Overexpression of NEK2 induces phosphorylation of endogenous SR proteins and affects the splicing activity of SRSF1 toward reporter minigenes and endogenous targets, independently of SRPK1. Conversely, knockdown of NEK2, like that of SRSF1, induces expression of pro-apoptotic variants from SRSF1-target genes and sensitizes cells to apoptosis. Our results identify NEK2 as a novel splicing factor kinase and suggest that part of its oncogenic activity may be ascribed to its ability to modulate alternative splicing, a key step in gene expression regulation that is frequently altered in cancer cells
SINCONAPP: A Computerized learning tool for CBCT normal anatomy and variants of the nose and paranasal sinuses
1. Purpose
To supply an useful learning tool aimed to interactively display on mobile devices normal anatomy
and variants of the nose and paranasal sinuses as seen on CBCT images.
2. Methods and Materials
Images
Images of the nose and paranasal sinuses were derived by a study series acquired by a CBCT device.
CBCT studies of the paranasal sinuses were acquired in patients referred for nasal obstruction or
sinusitis with the following parameters: 90 kVp, 12.5 mA, 20 s rotation time, FOV 13 x 14.5 cm, 0.25 x
0.25 x 0.25 mm voxel size.
Software
The application has been developed for iOS based mobile devices through the platform XCode
provided by Apple®, and it is developed using the Objective-C programming language. The
application has been configured as Master-Detail. This configuration splits the mobile device display in
two panels. The left panel displays a list of the interesting items, while the right panel shows the
relative details. Touching an item from the menu on the left panel, the textual description is shown on
the same side, while the panel on the right will show the relative image. The application allows interactively navigation through normal anatomy and variants of the nose and
paranasal sinuses, as represented on CBCT images in axial, sagittal and coronal planes. Cross-reference
images to localize the same anatomic structures on different section planes are available. The
navigation is intuitive, with multiple shortcuts. Different labels have been proposed in accordance
with the specific anatomic lessic of the district and current literature references. High image quality
with a zooming tool are available. 4. Conclusion
An App for IOs devices was developed, that can represent an useful educational tool for medical
students, residents and continuous medical education in radiology and other medical specialties
dealing with nose and paranasal sinuses. This interactive atlas based on CBCT images could be also an
useful option to be implemented on CBCT software
In vivo and in vitro evidence that intrinsic upper- and lower-limb skeletal muscle function is unaffected by ageing and disuse in oldest-old humans
Aim: To parse out the impact of advanced ageing and disuse on skeletal
muscle function, we utilized both in vivo and in vitro techniques to comprehensively
assess upper- and lower-limb muscle contractile properties in
8 young (YG; 25 6 years) and 8 oldest-old mobile (OM; 87 5 years)
and 8 immobile (OI; 88 4 years) women.
Methods: In vivo, maximal voluntary contraction (MVC), electrically
evoked resting twitch force (RT), and physiological cross-sectional area
(PCSA) of the quadriceps and elbow flexors were assessed. Muscle biopsies
of the vastus lateralis and biceps brachii facilitated the in vitro assessment
of single fibre-specific tension (Po).
Results: In vivo, compared to the young, both the OM and OI exhibited
a more pronounced loss of MVC in the lower limb [OM (60%) and OI
(75%)] than the upper limb (OM = 51%; OI = 47%). Taking into
account the reduction in muscle PCSA (OM = 10%; OI = 18%), only
evident in the lower limb, by calculating voluntary muscle-specific force,
the lower limb of the OI (40%) was more compromised than the OM
(13%). However, in vivo, RT in both upper and lower limbs (approx.
9.8 N m cm
2) and Po (approx. 123 mN mm
2), assessed in vitro, implies
preserved intrinsic contractile function in all muscles of the oldest-old and
were well correlated (r = 0.81).
Conclusion: These findings suggest that in the oldest-old, neither
advanced ageing nor disuse, per se, impacts intrinsic skeletal muscle function,
as assessed in vitro. However, in vivo, muscle function is attenuated
by age and exacerbated by disuse, implicating factors other than skeletal
muscle, such as neuromuscular control, in this diminution of function.
Keywords in vitro, in vivo, oldest-old, sarcopeni
A new technique for the histological diagnosis of Paget's disease of the breast using a semiautomated core needle biopsy with a 14-gauge needle
MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice
Background: Aldosterone is a critical pathological driver for cardiac and renal diseases. We recently discovered that mutant atrial natriuretic peptide (MANP), a novel atrial natriuretic peptide (ANP) analog, possessed more potent aldosterone inhibitory action than ANP in vivo. MANP and natriuretic peptide (NP)-augmenting therapy sacubitril/valsartan are under investigations for human hypertension treatment. Understanding the elusive mechanism of aldosterone inhibition by NPs remains to be a priority. Conflicting results were reported on the roles of the pGC-A (particulate guanylyl cyclase A receptor) and NP clearance receptor in aldosterone inhibition. Furthermore, the function of PKG (protein kinase G) and PDEs (phosphodiesterases) on aldosterone regulation are not clear. Methods: In the present study, we investigated the molecular mechanism of aldosterone regulation in a human adrenocortical cell line H295R and in mice. Results: We first provided evidence to show that pGC-A, not NP clearance receptor, mediates aldosterone inhibition. Next, we confirmed that MANP inhibits aldosterone via PDE2 (phosphodiesterase 2) not PKG, with specific agonists, antagonists, siRNA silencing, and fluorescence resonance energy transfer experiments. Further, the inhibitory effect is mediated by a reduction of intracellular Ca2+ levels. We then illustrated that MANP directly reduces aldosterone synthase CYP11B2 (cytochrome p450 family 11 subfamily b member 2) expression via PDE2. Last, in PDE2 knockout mice, consistent with in vitro findings, embryonic adrenal CYP11B2 is markedly increased. Conclusions: Our results innovatively explore and expand the NP/pGC-A/3',5', cyclic guanosine monophosphate (cGMP)/PDE2 pathway for aldosterone inhibition by MANP in vitro and in vivo. In addition, our data also support the development of MANP as a novel ANP analog drug for aldosterone excess treatment
The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer. Most patients present with advanced disease at diagnosis, which only permits palliative chemotherapeutic treatments. RNA dysregulation is a hallmark of most human cancers, including PDAC. To test the impact of RNA processing dysregulation on PDAC pathology, we performed a bioinformatics analysis to identify RNA-binding proteins (RBPs) associated with prognosis. Among the 12 RBPs associated with progression-free survival, we focused on MEX3A because it was recently shown to mark an intestinal stem cell population that is refractory to chemotherapeutic treatments, a typical feature of PDAC. Increased expression of MEX3A was correlated with higher disease stage in PDAC patients and with tumor development in a mouse model of PDAC. Depletion of MEX3A in PDAC cells enhanced sensitivity to chemotherapeutic treatment with gemcitabine, whereas its expression was increased in PDAC cells selected upon chronic exposure to the drug. RNA-sequencing analyses highlighted hundreds of genes whose expression is sensitive to MEX3A expression, with significant enrichment in cell cycle genes. MEX3A binds to its target mRNAs, like cyclin-dependent kinase 6 (CDK6), and promotes their stability. Accordingly, knockdown of MEX3A caused a significant reduction in PDAC cell proliferation and in progression to the S phase of the cell cycle. These findings uncover a novel role for MEX3A in the acquisition and maintenance of chemoresistance by PDAC cells, suggesting that it may represent a novel therapeutic target for PDAC
Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI.
Abstract: Several respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five influenza seasons before the emergence of SARS-CoV-2 epidemic in Sicily (Italy). Respiratory specimens from ILI outpatients and SARI inpatients were collected in the framework of the Italian Network for the Influenza Surveillance and molecularly tested for hRSV-A and hRSV-B. Overall, 8.1% of patients resulted positive for hRSV. Prevalence peaked in the age-groups <5 years old (range: 17.6–19.1%) and ≥50 years old (range: 4.8–5.1%). While the two subgroups co-circulated throughout the study period, hRSV-B was slightly predominant over hRSV-A, except for the season 2019–2020 when hRSV-A strongly prevailed (82.9%). In the community setting, the distribution of hRSV subgroups was balanced (47.8% vs. 49.7% for hRSV-A and hRSV-B, respectively), while most infections identified in the hospital setting were caused by hRSV-B (69.5%); also, this latter one was more represented among hRSV cases with underlying diseases, as well as among those who developed a respiratory complication. The molecular surveillance of hRSV infections may provide a valuable insight into the epidemiological features of ILI/SARI. Our findings add new evidence to the existing knowledge on viral aetiology of ILI and SARI in support of public health strategies and may help to define high-risk categories that could benefit from currently available and future vaccines
- …